Business
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."","length":513,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/d2526cefeceefc8edb647aca7425fdd3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m77crSQ88lwpPYs.eM.I3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/d2526cefeceefc8edb647aca7425fdd3","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/e_AeViMWvVUl9eWiXqelxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/d2526cefeceefc8edb647aca7425fdd3","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/71ad4153-9279-4e7f-ad35-82d0e893995a/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.","length":385,"tagName":"p"},{"type":"text","content":"A copy of the updated report can be obtained directly from Ascendiant Capital Markets: LINK","length":91,"tagName":"p"},{"type":"text","content":"About IGC Pharma (dba IGC):IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Ou...